US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI) — PROXY  

Hairy Cell Leukemia Clinical Trial

Official title: US Post-Marketing Retrospective Observational Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)(TM)

Status Terminated

Clinical Trial Summary

This study is being conducted to satisfy a post-marketing requirement (PMR) to provide evidence characterizing 1) the safety of moxetumomab pasudotox-tdfk in patients who are 65 years of age and older and/or 2) the safety of moxetumomab pasudotox-tdfk in patients who have moderate renal impairment defined as an estimated GFR of 30-59 ml/min

Clinical Trial Description

The pivotal Phase 3 study (Study 1053) supported full approval of moxetumomab pasudotox-tdfk from the US Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a PNA, on 13 September 2018. Since HCL is a rare disease, clinical research has limited information concerning the safety of moxetumomab pasudotox-tdfk in elderly patient populations and patients with moderate renal impairment.This study is being conducted to satisfy a post-marketing requirement (PMR) to provide evidence characterizing the safety of moxetumomab in these patients. ;

Related Conditions & MeSH terms

• Hairy Cell Leukemia
• Leukemia, Hairy Cell

• NCT number: NCT04125290
• Study type: Observational
• Source: AstraZeneca
• Status: Terminated
• Start date: December 9, 2019
• Completion date: June 21, 2021